BioSpace News Archive

Business

Henry Schein Expands Access to Point-of-Care Testing, PPE, and Essential Medical Supplies to Help Meet the Needs of Patients

Henry Schein, Inc. (Nasdaq: HSIC) today announced that it has signed a cooperative contract with OMNIA Partners.

December 13, 2021
·
4 min read
Drug Development

Catamaran Bio Presents Preclinical Data Supporting CAT-248, an Off-the-Shelf CD70-Targeted CAR-NK Cell Therapy for the Treatment of CD70-Expressing Cancers

Catamaran Bio , Inc. today announced preclinical data that demonstrate key capabilities of its TAILWINDTM platform being applied to develop CAT-248, an allogeneic CD70-targeted CAR-NK cell therapy.

December 13, 2021
·
4 min read
Deals

Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization

Bristol Myers Squibb (NYSE: BMY) today announced that on December 10, 2021, its Board of Directors approved an increase in the quarterly dividend and authorized an additional multi-year share repurchase program.

December 13, 2021
·
5 min read
FDA

InterVene’s BlueLeaf Endovenous Valve Formation (EVF) System Granted Breakthrough Device Designation by the FDA

InterVene Inc. announced today that it has received Breakthrough Device Designation by the FDA for the company’s BlueLeaf ® Endovenous Valve Formation System.

December 13, 2021
·
3 min read
Drug Development

4D Pharma Announces Positive Topline Results From Part a of Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma

4D pharma plc today announces positive topline results from Part A of phase I/II clinical trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.

December 13, 2021
·
8 min read
Deals

Mednow Closes Acquisition of Infusicare Pharmacy

Mednow Inc. is pleased to announce that further to its press release dated November 18, 2021, it has closed the acquisition of Infusicare Canada Inc. (“ Infusicare ”) for a cash payment of C$1.85M.

December 13, 2021
·
6 min read
Drug Development

BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough

BELLUS Health Inc. today announced that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of RCC achieved statistical significance on the primary endpoint with 34% placebo-adjusted reduction in 24-hour cough frequency observed (p ≤ 0.005) at day 28.

December 13, 2021
·
11 min read
Genetown

Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. today announced that the first patient has been dosed with NTLA-2002, the company’s in vivo CRISPR/Cas9 genome editing candidate being developed as a single-dose therapy to prevent attacks in people living with hereditary angioedema (HAE).

December 13, 2021
·
6 min read
Business

HCW Biologics’ Founder and CEO Dr. Hing C. Wong Named Weaver H. Gaines Entrepreneur of the Year

HCW Biologics Inc. announced today Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, was named the 2021 Weaver H. Gaines Entrepreneur of the Year by BioFlorida.

December 13, 2021
·
7 min read
Business

Acerus Announces Amendments to Loan Facilities

Acerus Pharmaceuticals Corporation today announced that it has entered into an amending agreement with First Generation Capital Inc. to increase the existing subordinated secured loan facility from US$15 million to US$25 million.

December 13, 2021
·
4 min read